ERBB2 and breast carcinoma: In 2016, a phase I clinical trial demonstrated that a 68Ga-HER2 Nbs 2Rs15d was able to detect primary tumor and distant metastases in breast cancer patients already 60 min post-injection, without any adverse effects [76,77].